Pfizer Cuts Revenue Goal,
Touts Earnings Growth

NEW YORK -- Pfizer Inc. reduced its previously stated revenue target for this year, in part because of adverse effects of the strong dollar, but said earnings growth will remain strong.

The world's largest drug maker told analysts that earnings aren't expected to suffer in part because sales of drugs with high profit margins are running $200 million ahead of the company's previous plans for the year.